Statin Therapy in Rheumatoid ArthritisA Cost-Effectiveness and Value-of-Information Analysis

被引：0
|
作者：
Nick Bansback
Roberta Ara
Sue Ward
Aslam Anis
Hyon K. Choi
机构：
[1] St Paul’s Hospital,Centre for Health Evaluation and Outcome Sciences
[2] University of Sheffield,School of Health and Related Research, Health Economics and Decision Sciences
[3] University of British Columbia,Department of Healthcare and Epidemiology
[4] University of British Columbia,Rheumatology Division, Department of Medicine, Arthritis Research Centre of Canada, Vancouver General Hospital
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Rheumatoid Arthritis; Statin; Rheumatoid Arthritis Patient; Atorvastatin; Statin Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: HMG-CoA reductase inhibitors (statins) are potentially excellent candidate agents for patients with rheumatoid arthritis (RA). They reduce both cardiovascular risks and RA disease activity.
引用
收藏
页码：25 / 37
页数：12
相关论文
共 50 条
  • [41] Therapy of hepatitis C: Cost-effectiveness analysis
    Koff, RS
    HEPATOLOGY, 1997, 26 (03) : S152 - S155
  • [42] Gene therapy in hemophilia A: a cost-effectiveness analysis
    Machin, Nicoletta
    Ragni, Margaret V.
    Smith, Kenneth J.
    BLOOD ADVANCES, 2018, 2 (14) : 1792 - 1798
  • [43] Cost-Effectiveness Analysis of individualized Diabetes Therapy
    Pavlicek, V.
    DIABETOLOGE, 2018, 14 (03): : 180 - 181
  • [44] Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis
    Feng, Tianyu
    Zhang, Xiaolin
    Xu, Jiaying
    Gao, Shang
    Yu, Xihe
    INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2025, 24 (01)
  • [45] Value-of-information analysis of a fracture prediction method
    Almansour A.
    Laubach S.E.
    Eric Bickel J.
    Schultz R.A.
    1600, Society of Petroleum Engineers (SPE) (23): : 811 - 823
  • [46] Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)
    Barton, Garry R.
    Briggs, Andrew H.
    Fenwick, Elisabeth A. L.
    VALUE IN HEALTH, 2008, 11 (05) : 886 - 897
  • [47] Fighting global AIDS: the value of cost-effectiveness analysis
    Kahn, JG
    Marseille, E
    AIDS, 2000, 14 (16) : 2609 - 2610
  • [48] RHEUMATOID ARTHRITIS, COST-EFFECTIVENESS ANALYSIS OF BIOSIMILAR TOCILIZUMAB IN SPAIN
    Perez-Ruiz, F.
    Crespo Diz, C.
    Crespo, C.
    Cerezales, M.
    Guigini, M. A.
    Peinado Fabregat, J., I
    Schoenenberger, J. A.
    Climente, M.
    VALUE IN HEALTH, 2024, 27 (12) : S128 - S129
  • [49] ABATACEPT OR INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN VENEZUELA? A COST-EFFECTIVENESS ANALYSIS
    Alfonso-Cristancho, R.
    Serra, N.
    Aiello, E. C.
    Roa, C. N.
    VALUE IN HEALTH, 2011, 14 (03) : A126 - A127
  • [50] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF CARE
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    BOR, DH
    CLINICAL RESEARCH, 1987, 35 (03): : A744 - A744
12345